Ocular Therapeutix
Pharmaceuticals, 24 Crosby Dr, Bedford, Massachusetts, 01730, United States, 51-200 Employees
Phone Number: 78********
Who is OCULAR THERAPEUTIX
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of...
Read More
-
Headquarters: 24 Crosby Dr, Bedford, Massachusetts, 01730, United States
-
Date Founded: 2006
-
Employees: 51-200
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
-
CEO:
Antony Mattessich
Email
Phone
Industry: Pharmaceuticals
SIC Code: 1731
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from OCULAR THERAPEUTIX
Ocular Therapeutix Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Ocular Therapeutix
Answer: Ocular Therapeutix's headquarters are located at 24 Crosby Dr, Bedford, Massachusetts, 01730, United States
Answer: Ocular Therapeutix's phone number is 78********
Answer: Ocular Therapeutix's official website is https://ocutx.com
Answer: Ocular Therapeutix's revenue is $10 Million to $25 Million
Answer: Ocular Therapeutix's SIC: 1731
Answer: Ocular Therapeutix's NAICS: 325412
Answer: Ocular Therapeutix has 51-200 employees
Answer: Ocular Therapeutix is in Pharmaceuticals
Answer: Ocular Therapeutix contact info: Phone number: 78******** Website: https://ocutx.com
Answer: Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology, ElutyxTM. Ocular Therapeutix has built a robust product pipeline of drug delivery solutions developed to reduce the complexity and burden of the current standard of care and position itself to become a leader in the ophthalmic space. Ocular Therapeutix has a commercially available drug product, DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use. DEXTENZA is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and for the treatment of ocular itching associated with allergic conjunctivitis; the product is currently being marketed through a fully integrated specialty sales force. Ocular Therapeutixs lead clinical program AXPAXLITM (axitinib intravitreal implant), also referenced as laboratory code OTX-TKI, is currently being developed to treat wet AMD and diabetic retinopathy; other indications may also be pursued in due course. Other clinical programs include PAXTRAVATM (travoprost intracameral implant), also referenced as laboratory code OTX-TIC, for intracameral injection, for the treatment of elevated intraocular pressure in primary open-angle glaucoma or ocular hypertension, OTX-CSI (cyclosporine ophthalmic insert) for intracanalicular use, for the chronic treatment of dry eye disease, and OTX-DED (dexamethasone ophthalmic insert) for intracanalicular use, for the short-term treatment of the signs and symptoms of dry eye disease.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month